
Jacqueline A James

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5719794/publications.pdf Version: 2024-02-01



IACOLIELINE & JAMES

#	Article	IF	CITATIONS
1	QuPath: Open source software for digital pathology image analysis. Scientific Reports, 2017, 7, 16878.	1.6	3,854
2	Digital pathology and image analysis in tissue biomarker research. Methods, 2014, 70, 59-73.	1.9	162
3	Metastasis and Immune Evasion from Extracellular cGAMP Hydrolysis. Cancer Discovery, 2021, 11, 1212-1227.	7.7	139
4	HPV-Related Oropharynx Cancer in the United Kingdom: An Evolution in the Understanding of Disease Etiology. Cancer Research, 2016, 76, 6598-6606.	0.4	128
5	Identification and Validation of an Anthracycline/Cyclophosphamide–Based Chemotherapy Response Assay in Breast Cancer. Journal of the National Cancer Institute, 2014, 106, djt335.	3.0	91
6	Integrated tumor identification and automated scoring minimizes pathologist involvement and provides new insights to key biomarkers in breast cancer. Laboratory Investigation, 2018, 98, 15-26.	1.7	81
7	Swarm learning for decentralized artificial intelligence in cancer histopathology. Nature Medicine, 2022, 28, 1232-1239.	15.2	77
8	Validation of the systematic scoring of immunohistochemically stained tumour tissue microarrays using <i>QuPath</i> digital image analysis. Histopathology, 2018, 73, 327-338.	1.6	63
9	The prognostic significance of the aberrant extremes of p53 immunophenotypes in breast cancer. Histopathology, 2014, 65, 340-352.	1.6	59
10	Evaluation of PTGS2 Expression, PIK3CA Mutation, Aspirin Use and Colon Cancer Survival in a Population-Based Cohort Study. Clinical and Translational Gastroenterology, 2017, 8, e91.	1.3	56
11	Identifying mismatch repairâ€deficient colon cancer: nearâ€perfect concordance between immunohistochemistry and microsatellite instability testing in a large, populationâ€based series. Histopathology, 2021, 78, 401-413.	1.6	55
12	Recommendations for determining HPV status in patients with oropharyngeal cancers under TNM8 guidelines: a two-tier approach. British Journal of Cancer, 2019, 120, 827-833.	2.9	51
13	Fusobacterium nucleatum and oral cancer: a critical review. BMC Cancer, 2021, 21, 1212.	1.1	50
14	Digital pathology and artificial intelligence will be key to supporting clinical and academic cellular pathology through COVID-19 and future crises: the PathLAKE consortium perspective. Journal of Clinical Pathology, 2021, 74, 443-447.	1.0	49
15	Immune status is prognostic for poor survival in colorectal cancer patients and is associated with tumour hypoxia. British Journal of Cancer, 2020, 123, 1280-1288.	2.9	45
16	Automated Tumour Recognition and Digital Pathology Scoring Unravels New Role for PD-L1 in Predicting Good Outcome in ER-/HER2+ Breast Cancer. Journal of Oncology, 2018, 2018, 1-14.	0.6	44
17	Automated tumor analysis for molecular profiling in lung cancer. Oncotarget, 2015, 6, 27938-27952.	0.8	43
18	POU2F1 activity regulates HOXD10 and HOXD11 promoting a proliferative and invasive phenotype in Head and Neck cancer. Oncotarget, 2014, 5, 8803-8815.	0.8	43

JACQUELINE A JAMES

#	Article	IF	CITATIONS
19	Critical Appraisal of Programmed Death Ligand 1 Reflex Diagnostic Testing: Current Standards and Future Opportunities. Journal of Thoracic Oncology, 2019, 14, 45-53.	0.5	42
20	RNAscope <i>in situ</i> hybridization confirms mRNA integrity in formalin-fixed, paraffin-embedded cancer tissue samples. Oncotarget, 2017, 8, 93392-93403.	0.8	41
21	Comprehensive molecular pathology analysis of small bowel adenocarcinoma reveals novel targets with potential for clinical utility. Oncotarget, 2015, 6, 20863-20874.	0.8	41
22	Quantification of HER2 heterogeneity in breast cancer–implications for identification of sub-dominant clones for personalised treatment. Scientific Reports, 2016, 6, 23383.	1.6	38
23	Tissue-based next generation sequencing: application in a universal healthcare system. British Journal of Cancer, 2017, 116, 553-560.	2.9	38
24	Molecular profiling of signet ring cell colorectal cancer provides a strong rationale for genomic targeted and immune checkpoint inhibitor therapies. British Journal of Cancer, 2017, 117, 203-209.	2.9	38
25	Statin use, candidate mevalonate pathway biomarkers, and colon cancer survival in a population-based cohort study. British Journal of Cancer, 2017, 116, 1652-1659.	2.9	37
26	Transcriptional upregulation of c-MET is associated with invasion and tumor budding in colorectal cancer. Oncotarget, 2016, 7, 78932-78945.	0.8	36
27	Improving the Diagnostic Accuracy of the PD-L1 Test with Image Analysis and Multiplex Hybridization. Cancers, 2020, 12, 1114.	1.7	34
28	Molecular pathology – The value of an integrative approach. Molecular Oncology, 2014, 8, 1163-1168.	2.1	32
29	Building a â€~Repository of Science': The importance ofÂintegrating biobanks within molecular pathology programmes. European Journal of Cancer, 2016, 67, 191-199.	1.3	31
30	The Northern Ireland Biobank: A Cancer Focused Repository of Science. Open Journal of Bioresources, 2018, 5, .	1.5	30
31	Analysis of wntless (WLS) expression in gastric, ovarian, and breast cancers reveals a strong association with HER2 overexpression. Modern Pathology, 2015, 28, 428-436.	2.9	27
32	Quality assurance guidance for scoring and reporting for pathologists and laboratories undertaking clinical trial work. Journal of Pathology: Clinical Research, 2019, 5, 91-99.	1.3	21
33	The adaptive immune and immune checkpoint landscape of neoadjuvant treated esophageal adenocarcinoma using digital pathology quantitation. BMC Cancer, 2020, 20, 500.	1.1	20
34	ΔNp63Î ³ /SRC/Slug Signaling Axis Promotes Epithelial-to-Mesenchymal Transition in Squamous Cancers. Clinical Cancer Research, 2018, 24, 3917-3927.	3.2	19
35	Immune activation by DNA damage predicts response to chemotherapy and survival in oesophageal adenocarcinoma. Gut, 2019, 68, 1918-1927.	6.1	18
36	PTEN mRNA detection by chromogenic, RNA in situ technologies: a reliable alternative to PTEN immunohistochemistry. Human Pathology, 2016, 47, 95-103.	1.1	17

JACQUELINE A JAMES

#	Article	IF	CITATIONS
37	A Means of Assessing Deep Learning-Based Detection of ICOS Protein Expression in Colon Cancer. Cancers, 2021, 13, 3825.	1.7	17
38	Alcohol intake, tobacco smoking, and esophageal adenocarcinoma survival: a molecular pathology epidemiology cohort study. Cancer Causes and Control, 2020, 31, 1-11.	0.8	16
39	PICan: An integromics framework for dynamic cancer biomarker discovery. Molecular Oncology, 2015, 9, 1234-1240.	2.1	15
40	MAPKAPK2 (MK2) inhibition mediates radiation-induced inflammatory cytokine production and tumor growth in head and neck squamous cell carcinoma. Oncogene, 2019, 38, 7329-7341.	2.6	15
41	Comparison of Molecular Assays for HPV Testing in Oropharyngeal Squamous Cell Carcinomas: A Population-Based Study in Northern Ireland. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 31-38.	1.1	14
42	Glucose transporter 1 expression as a marker of prognosis in oesophageal adenocarcinoma. Oncotarget, 2018, 9, 18518-18528.	0.8	13
43	Punctate <scp>MLH</scp> 1 mismatch repair immunostaining in colorectal cancer. Histopathology, 2019, 74, 795-797.	1.6	11
44	PD-L1 Multiplex and Quantitative Image Analysis for Molecular Diagnostics. Cancers, 2021, 13, 29.	1.7	11
45	Evolutionary genetic algorithm identifies <i>IL2RB</i> as a potential predictive biomarker for immune-checkpoint therapy in colorectal cancer. NAR Genomics and Bioinformatics, 2021, 3, lqab016.	1.5	10
46	p16 as a prognostic indicator in ovarian/tubal highâ€grade serous carcinoma. Histopathology, 2016, 68, 615-618.	1.6	8
47	Colonic epithelial cathelicidin (<scp>LL</scp> â€37) expression intensity is associated with progression of colorectal cancer and presence of <scp>CD8</scp> ⁺ T cell infiltrate. Journal of Pathology: Clinical Research, 2021, 7, 495-506.	1.3	8
48	Molecular classification of non-invasive breast lesions for personalised therapy and chemoprevention. Oncotarget, 2015, 6, 43244-43254.	0.8	8
49	Practical guide for the comparison of two next-generation sequencing systems for solid tumour analysis in a universal healthcare system. Journal of Clinical Pathology, 2019, 72, 225-231.	1.0	7
50	Vitamin D receptor as a marker of prognosis in oesophageal adenocarcinoma: a prospective cohort study. Oncotarget, 2018, 9, 34347-34356.	0.8	7
51	Sex hormone receptor expression and survival in esophageal adenocarcinoma: a prospective cohort study. Oncotarget, 2018, 9, 35300-35312.	0.8	6
52	Delivering a researchâ€enabled multistakeholder partnership for enhanced patient care at a population level: The Northern Ireland Comprehensive Cancer Program. Cancer, 2016, 122, 664-673.	2.0	5
53	The Potential of Digital Image Analysis to Determine Tumor Cell Content in Biobanked Formalin-Fixed, Paraffin-Embedded Tissue Samples. Biopreservation and Biobanking, 2021, 19, 324-331.	0.5	5
54	Ultra-Fast Processing of Gigapixel Tissue MicroArray Images Using High Performance Computing. Analytical Cellular Pathology, 2010, 33, 271-285.	0.7	4

#	Article	IF	CITATIONS
55	General Roadmap and Core Steps for the Development of Al Tools in Digital Pathology. Diagnostics, 2022, 12, 1272.	1.3	4
56	Orthogonal <i>MET</i> analysis in a populationâ€representative stage II–III colon cancer cohort: prognostic and potential therapeutic implications. Molecular Oncology, 2021, 15, 3317-3328.	2.1	3
57	Association of a DNA damage response deficiency (DDRD) assay and prognosis in early-stage esophageal adenocarcinoma Journal of Clinical Oncology, 2014, 32, 4015-4015.	0.8	3
58	A biobank perspective on use of tissue samples donated by trial participants. Lancet Oncology, The, 2022, 23, e205.	5.1	2
59	High PTGS2 expression in postâ€neoadjuvant chemotherapyâ€treated oesophageal adenocarcinoma is associated with improved survival: a populationâ€based cohort study. Histopathology, 2019, 74, 587-596.	1.6	1
60	PD-L1 expression and response to neo-adjuvant chemotherapy in esophageal adenocarcinoma Journal of Clinical Oncology, 2017, 35, 4023-4023.	0.8	1